Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030
The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.
By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.
The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.
In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.
In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America's well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.
The primary interviews conducted for this report can be categorized as follows:
Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following :
By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.
By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.
The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.
In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.
In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America's well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
- By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%
Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following :
- Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
- Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
- Pipeline Analysis: Comprehensive information about products under clinical trials.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 YEARS CONSIDERED
1.4.2 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
2.5 MARKET BREAKDOWN & DATA TRIANGULATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024)
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications
5.2.1.2 Technological advancements
5.2.1.3 Growing government investments in life science research & synthetic biology
5.2.1.4 Growing focus on precision/personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Complexities associated with therapeutic oligonucleotides
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing R&D investments by key players in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Lack of standard regulations
5.2.4.2 Delivery of oligonucleotide drugs to specific targets
5.3 INDUSTRY TRENDS
5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ROLE IN ECOSYSTEM
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Solid-phase synthesis
5.7.1.2 Liquid-phase synthesis
5.7.1.3 Enzymatic oligo synthesis
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Polymerase chain reaction (PCR)
5.7.2.2 Next-generation sequencing
5.7.2.3 Microarray analysis
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 CRISPR
5.7.3.2 Lipid nanoparticles
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022?2024
5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022?2024
5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022?2024
5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
5.9 PATENT ANALYSIS
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
5.10 PIPELINE ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA (HS CODE 293499)
5.11.2 EXPORT DATA (HS CODE 293499)
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 TARIFF & REGULATORY LANDSCAPE
5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00)
5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022?2025
5.13.1.2 Impact of Tariffs on pricing & supply chain
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.13.3 REGULATORY FRAMEWORK
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 DEGREE OF COMPETITION
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 THREAT OF NEW ENTRANTS
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA FOR END USERS
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
5.17 INVESTMENT/FUNDING SCENARIO
5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19.1 KEY TARIFF RATES
5.19.2 PRICE IMPACT ANALYSIS
5.19.3 KEY IMPACT ON VARIOUS REGIONS
5.19.3.1 US
5.19.3.2 Europe
5.19.3.3 APAC
5.19.3.4 Rest of the World
5.19.4 END-USE INDUSTRY IMPACT
5.19.4.1 Hospitals
5.19.4.2 Pharmaceutical & biotechnology companies
5.19.4.3 Diagnostic laboratories
5.19.4.4 CROs & CDMOs
5.19.4.5 Academic & research institutes
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 OLIGONUCLEOTIDE-BASED DRUGS
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
6.2.1.1 Antisense oligonucleotide-based drugs
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
6.2.1.2 siRNA oligonucleotide-based drugs
6.2.1.2.1 Large pipeline of products to favor market growth
6.2.1.3 Other oligonucleotide-based drugs
6.3 SYNTHESIZED OLIGONUCLEOTIDES
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
6.3.1.1 Primers
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
6.3.1.2 Probes
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
6.3.1.3 DNA oligonucleotides
6.3.1.3.1 Diverse usage of DNA oligos to support market growth
6.3.1.4 RNA oligonucleotides
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
6.3.1.5 Other synthesized oligonucleotides
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
6.3.2.1 Custom oligonucleotides
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
6.3.2.2 Predesigned oligonucleotides
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
6.4 REAGENTS & CONSUMABLES
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
6.5 EQUIPMENT
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 THERAPEUTIC APPLICATIONS
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
7.2.1.1 Neurological disorders
7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market
7.2.1.2 Rare diseases
7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth
7.2.1.3 Other diseases
7.3 RESEARCH APPLICATIONS
7.3.1 PCR
7.3.1.1 Increasing use of PCR in molecular biology research to drive market
7.3.2 SEQUENCING
7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market
7.3.3 OTHER RESEARCH APPLICATIONS
7.4 DIAGNOSTIC APPLICATIONS
7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
8.4 DIAGNOSTIC LABORATORIES
8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
8.6 ACADEMIC RESEARCH INSTITUTES
8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
9.2.2 US
9.2.2.1 Government initiatives and strategic developments by leading players to drive market
9.2.3 CANADA
9.2.3.1 Strong research infrastructure and availability of funding to support market growth
9.3 EUROPE
9.3.1 EUROPE: MACROECONOMIC OUTLOOK
9.3.2 GERMANY
9.3.2.1 Government & private funding investments towards health research to drive market
9.3.3 UK
9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market
9.3.4 FRANCE
9.3.4.1 Favorable government initiatives for genomics research to boost demand
9.3.5 ITALY
9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth
9.3.6 SPAIN
9.3.6.1 Favorable funding investments for biomedical research to drive market
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
9.4.2 CHINA
9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market
9.4.3 JAPAN
9.4.3.1 Growing research initiatives & strategic developments to boost demand
9.4.4 INDIA
9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market
9.4.5 AUSTRALIA
9.4.5.1 Increasing government initiatives and research funding to support market growth
9.4.6 SOUTH KOREA
9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
9.5.2 BRAZIL
9.5.2.1 Availability of leading oligo-based therapies to support market growth
9.5.3 MEXICO
9.5.3.1 Growing adoption of NGS technology to drive market
9.5.4 ARGENTINA
9.5.4.1 Increasing research collaborations and government support to boost market
9.5.5 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia (KSA)
9.6.2.1.1 Increasing focus on research & government support to propel market
9.6.2.2 United Arab Emirates (UAE)
9.6.2.2.1 Growing focus on life sciences research to fuel market
9.6.2.3 Other GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
9.7.2 AFRICA: MACROECONOMIC OUTLOOK
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022?2024
10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022?2024
10.4 MARKET SHARE ANALYSIS
10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
10.6.5 COMPANY FOOTPRINT:
10.6.5.1 Company footprint (Research & diagnostic applications)
10.6.5.2 Region footprint (Research & diagnostic applications)
10.6.5.3 Product footprint (Research & diagnostic applications)
10.6.5.4 Application footprint (Research & diagnostic applications)
10.6.5.5 Company footprint (Therapeutic applications)
10.6.5.6 Region footprint (Therapeutic applications)
10.6.5.7 Product footprint (Therapeutic applications)
10.6.5.8 Application footprint (Therapeutic applications)
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7.5.1 Detailed list of key startups/SMEs
10.7.5.2 Competitive benchmarking of startups/SMEs
10.8 COMPANY VALUATION & FINANCIAL METRICS
10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT APPROVALS
11 COMPANY PROFILES
11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.3.3 Other developments
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 THERMO FISHER SCIENTIFIC INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MERCK KGAA
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Deals
11.1.3.3.2 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 LGC LIMITED
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 EUROFINS SCIENTIFIC
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Deals
11.1.5.3.2 Expansions
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 AGILENT TECHNOLOGIES, INC.
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 KANEKA CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Expansions
11.1.8 MARAVAI LIFESCIENCES
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 AZENTA US INC.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 TWIST BIOSCIENCE
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 GENSCRIPT
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
11.2.1 BIOGEN
11.2.1.1 Business overview
11.2.1.2 Products offered
11.2.1.3 Recent developments
11.2.1.3.1 Product approvals
11.2.1.3.2 Deals
11.2.1.3.3 Expansions
11.2.1.4 MnM view
11.2.1.4.1 Key strengths
11.2.1.4.2 Strategic choices
11.2.1.4.3 Weaknesses & competitive threats
11.2.2 ALNYLAM PHARMACEUTICALS, INC.
11.2.2.1 Business overview
11.2.2.2 Products offered
11.2.2.3 Recent developments
11.2.2.3.1 Product approvals
11.2.2.3.2 Deals
11.2.2.4 MnM view
11.2.2.4.1 Key strengths
11.2.2.4.2 Strategic choices
11.2.2.4.3 Weaknesses & competitive threats
11.2.3 SAREPTA THERAPEUTICS, INC.
11.2.3.1 Business overview
11.2.3.2 Products offered
11.2.3.3 Recent developments
11.2.3.3.1 Product approvals
11.2.3.3.2 Expansions
11.2.3.4 MnM view
11.2.3.4.1 Key strengths
11.2.3.4.2 Strategic choices
11.2.3.4.3 Weaknesses & competitive threats
11.2.4 ASTRAZENECA
11.2.4.1 Business overview
11.2.4.2 Products offered
11.2.4.3 Recent developments
11.2.4.3.1 Deals
11.2.4.3.2 Product Approvals
11.2.4.4 MnM view
11.2.4.4.1 Key strengths
11.2.4.4.2 Strategic choices
11.2.4.4.3 Weaknesses & competitive threats
11.2.5 ASTELLAS PHARMA INC.
11.2.5.1 Business overview
11.2.5.2 Products offered
11.2.5.3 Recent developments
11.2.5.3.1 Deals
11.2.5.3.2 Product approvals
11.2.5.4 MnM view
11.2.5.4.1 Key strengths
11.2.5.4.2 Strategic choices
11.2.5.4.3 Weaknesses & competitive threats
11.2.6 JAZZ PHARMACEUTICALS PLC
11.2.6.1 Business overview
11.2.6.2 Products offered
11.2.7 NIPPON SHINYAKU, CO. LTD.
11.2.7.1 Business overview
11.2.7.2 Products offered
11.2.7.3 Recent developments
11.2.7.3.1 Deals
11.2.8 IONIS PHARMACEUTICALS, INC.
11.2.8.1 Business overview
11.2.8.2 Products offered
11.2.8.3 Recent developments
11.2.8.3.1 Product Approvals
11.2.8.3.2 Deals
11.2.9 NOVARTIS AG
11.2.9.1 Business overview
11.2.9.2 Products offered
11.2.9.3 Recent developments
11.2.9.3.1 Product Approvals
11.2.9.3.2 Deals
11.3 OTHER PLAYERS
11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
11.3.2 BIOLEGIO B.V.
11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
11.3.4 BIOCOMMA LIMITED
11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
11.3.6 BIO-SYNTHESIS, INC.
11.3.7 CREATIVE BIOGENE
11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 YEARS CONSIDERED
1.4.2 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
2.5 MARKET BREAKDOWN & DATA TRIANGULATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024)
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications
5.2.1.2 Technological advancements
5.2.1.3 Growing government investments in life science research & synthetic biology
5.2.1.4 Growing focus on precision/personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Complexities associated with therapeutic oligonucleotides
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing R&D investments by key players in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Lack of standard regulations
5.2.4.2 Delivery of oligonucleotide drugs to specific targets
5.3 INDUSTRY TRENDS
5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ROLE IN ECOSYSTEM
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Solid-phase synthesis
5.7.1.2 Liquid-phase synthesis
5.7.1.3 Enzymatic oligo synthesis
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Polymerase chain reaction (PCR)
5.7.2.2 Next-generation sequencing
5.7.2.3 Microarray analysis
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 CRISPR
5.7.3.2 Lipid nanoparticles
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022?2024
5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022?2024
5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022?2024
5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
5.9 PATENT ANALYSIS
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
5.10 PIPELINE ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA (HS CODE 293499)
5.11.2 EXPORT DATA (HS CODE 293499)
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 TARIFF & REGULATORY LANDSCAPE
5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00)
5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022?2025
5.13.1.2 Impact of Tariffs on pricing & supply chain
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.13.3 REGULATORY FRAMEWORK
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 DEGREE OF COMPETITION
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 THREAT OF NEW ENTRANTS
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA FOR END USERS
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
5.17 INVESTMENT/FUNDING SCENARIO
5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19.1 KEY TARIFF RATES
5.19.2 PRICE IMPACT ANALYSIS
5.19.3 KEY IMPACT ON VARIOUS REGIONS
5.19.3.1 US
5.19.3.2 Europe
5.19.3.3 APAC
5.19.3.4 Rest of the World
5.19.4 END-USE INDUSTRY IMPACT
5.19.4.1 Hospitals
5.19.4.2 Pharmaceutical & biotechnology companies
5.19.4.3 Diagnostic laboratories
5.19.4.4 CROs & CDMOs
5.19.4.5 Academic & research institutes
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 OLIGONUCLEOTIDE-BASED DRUGS
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
6.2.1.1 Antisense oligonucleotide-based drugs
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
6.2.1.2 siRNA oligonucleotide-based drugs
6.2.1.2.1 Large pipeline of products to favor market growth
6.2.1.3 Other oligonucleotide-based drugs
6.3 SYNTHESIZED OLIGONUCLEOTIDES
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
6.3.1.1 Primers
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
6.3.1.2 Probes
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
6.3.1.3 DNA oligonucleotides
6.3.1.3.1 Diverse usage of DNA oligos to support market growth
6.3.1.4 RNA oligonucleotides
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
6.3.1.5 Other synthesized oligonucleotides
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
6.3.2.1 Custom oligonucleotides
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
6.3.2.2 Predesigned oligonucleotides
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
6.4 REAGENTS & CONSUMABLES
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
6.5 EQUIPMENT
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 THERAPEUTIC APPLICATIONS
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
7.2.1.1 Neurological disorders
7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market
7.2.1.2 Rare diseases
7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth
7.2.1.3 Other diseases
7.3 RESEARCH APPLICATIONS
7.3.1 PCR
7.3.1.1 Increasing use of PCR in molecular biology research to drive market
7.3.2 SEQUENCING
7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market
7.3.3 OTHER RESEARCH APPLICATIONS
7.4 DIAGNOSTIC APPLICATIONS
7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
8.4 DIAGNOSTIC LABORATORIES
8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
8.6 ACADEMIC RESEARCH INSTITUTES
8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
9.2.2 US
9.2.2.1 Government initiatives and strategic developments by leading players to drive market
9.2.3 CANADA
9.2.3.1 Strong research infrastructure and availability of funding to support market growth
9.3 EUROPE
9.3.1 EUROPE: MACROECONOMIC OUTLOOK
9.3.2 GERMANY
9.3.2.1 Government & private funding investments towards health research to drive market
9.3.3 UK
9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market
9.3.4 FRANCE
9.3.4.1 Favorable government initiatives for genomics research to boost demand
9.3.5 ITALY
9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth
9.3.6 SPAIN
9.3.6.1 Favorable funding investments for biomedical research to drive market
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
9.4.2 CHINA
9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market
9.4.3 JAPAN
9.4.3.1 Growing research initiatives & strategic developments to boost demand
9.4.4 INDIA
9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market
9.4.5 AUSTRALIA
9.4.5.1 Increasing government initiatives and research funding to support market growth
9.4.6 SOUTH KOREA
9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
9.5.2 BRAZIL
9.5.2.1 Availability of leading oligo-based therapies to support market growth
9.5.3 MEXICO
9.5.3.1 Growing adoption of NGS technology to drive market
9.5.4 ARGENTINA
9.5.4.1 Increasing research collaborations and government support to boost market
9.5.5 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia (KSA)
9.6.2.1.1 Increasing focus on research & government support to propel market
9.6.2.2 United Arab Emirates (UAE)
9.6.2.2.1 Growing focus on life sciences research to fuel market
9.6.2.3 Other GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
9.7.2 AFRICA: MACROECONOMIC OUTLOOK
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022?2024
10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022?2024
10.4 MARKET SHARE ANALYSIS
10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
10.6.5 COMPANY FOOTPRINT:
10.6.5.1 Company footprint (Research & diagnostic applications)
10.6.5.2 Region footprint (Research & diagnostic applications)
10.6.5.3 Product footprint (Research & diagnostic applications)
10.6.5.4 Application footprint (Research & diagnostic applications)
10.6.5.5 Company footprint (Therapeutic applications)
10.6.5.6 Region footprint (Therapeutic applications)
10.6.5.7 Product footprint (Therapeutic applications)
10.6.5.8 Application footprint (Therapeutic applications)
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7.5.1 Detailed list of key startups/SMEs
10.7.5.2 Competitive benchmarking of startups/SMEs
10.8 COMPANY VALUATION & FINANCIAL METRICS
10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT APPROVALS
11 COMPANY PROFILES
11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.3.3 Other developments
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 THERMO FISHER SCIENTIFIC INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MERCK KGAA
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Deals
11.1.3.3.2 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 LGC LIMITED
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 EUROFINS SCIENTIFIC
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Deals
11.1.5.3.2 Expansions
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 AGILENT TECHNOLOGIES, INC.
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 KANEKA CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Expansions
11.1.8 MARAVAI LIFESCIENCES
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 AZENTA US INC.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 TWIST BIOSCIENCE
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 GENSCRIPT
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
11.2.1 BIOGEN
11.2.1.1 Business overview
11.2.1.2 Products offered
11.2.1.3 Recent developments
11.2.1.3.1 Product approvals
11.2.1.3.2 Deals
11.2.1.3.3 Expansions
11.2.1.4 MnM view
11.2.1.4.1 Key strengths
11.2.1.4.2 Strategic choices
11.2.1.4.3 Weaknesses & competitive threats
11.2.2 ALNYLAM PHARMACEUTICALS, INC.
11.2.2.1 Business overview
11.2.2.2 Products offered
11.2.2.3 Recent developments
11.2.2.3.1 Product approvals
11.2.2.3.2 Deals
11.2.2.4 MnM view
11.2.2.4.1 Key strengths
11.2.2.4.2 Strategic choices
11.2.2.4.3 Weaknesses & competitive threats
11.2.3 SAREPTA THERAPEUTICS, INC.
11.2.3.1 Business overview
11.2.3.2 Products offered
11.2.3.3 Recent developments
11.2.3.3.1 Product approvals
11.2.3.3.2 Expansions
11.2.3.4 MnM view
11.2.3.4.1 Key strengths
11.2.3.4.2 Strategic choices
11.2.3.4.3 Weaknesses & competitive threats
11.2.4 ASTRAZENECA
11.2.4.1 Business overview
11.2.4.2 Products offered
11.2.4.3 Recent developments
11.2.4.3.1 Deals
11.2.4.3.2 Product Approvals
11.2.4.4 MnM view
11.2.4.4.1 Key strengths
11.2.4.4.2 Strategic choices
11.2.4.4.3 Weaknesses & competitive threats
11.2.5 ASTELLAS PHARMA INC.
11.2.5.1 Business overview
11.2.5.2 Products offered
11.2.5.3 Recent developments
11.2.5.3.1 Deals
11.2.5.3.2 Product approvals
11.2.5.4 MnM view
11.2.5.4.1 Key strengths
11.2.5.4.2 Strategic choices
11.2.5.4.3 Weaknesses & competitive threats
11.2.6 JAZZ PHARMACEUTICALS PLC
11.2.6.1 Business overview
11.2.6.2 Products offered
11.2.7 NIPPON SHINYAKU, CO. LTD.
11.2.7.1 Business overview
11.2.7.2 Products offered
11.2.7.3 Recent developments
11.2.7.3.1 Deals
11.2.8 IONIS PHARMACEUTICALS, INC.
11.2.8.1 Business overview
11.2.8.2 Products offered
11.2.8.3 Recent developments
11.2.8.3.1 Product Approvals
11.2.8.3.2 Deals
11.2.9 NOVARTIS AG
11.2.9.1 Business overview
11.2.9.2 Products offered
11.2.9.3 Recent developments
11.2.9.3.1 Product Approvals
11.2.9.3.2 Deals
11.3 OTHER PLAYERS
11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
11.3.2 BIOLEGIO B.V.
11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
11.3.4 BIOCOMMA LIMITED
11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
11.3.6 BIO-SYNTHESIS, INC.
11.3.7 CREATIVE BIOGENE
11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 2 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016?2025)
TABLE 3 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 4 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 5 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022?2024
TABLE 6 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
TABLE 7 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
TABLE 8 AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 10 IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 11 IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)
TABLE 12 EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 13 EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)S
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 21 KEY COMPANIES IMPLEMENTING AI
TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 23 KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS.
TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 27 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2023–2030 (NUMBER OF VIALS)
TABLE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 35 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 36 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 37 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 44 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
TABLE 52 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 67 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 75 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)TABLE 80 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 82 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 103 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 104 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 111 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 133 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 155 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 160 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 191 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 196 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 229 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 236 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 237 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 238 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 239 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 240 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 241 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 242 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 244 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 246 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 247 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 248 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 249 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 252 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 253 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 254 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 257 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 261 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 263 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 264 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 266 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 269 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 270 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 271 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 273 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 274 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 277 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 278 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 279 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 282 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 285 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 287 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 289 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 290 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 293 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 295 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 296 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 297 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 298 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 301 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 303 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 306 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 309 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 311 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 312 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 313 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 314 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 318 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 320 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 322 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 323 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 326 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 328 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 330 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 331 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 332 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 334 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 336 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 338 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 339 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 342 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 344 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 346 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 347 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 348 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 350 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 351 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 352 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 354 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 355 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 356 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 358 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 360 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 362 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 363 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 364 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 366 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 368 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 370 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 371 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 372 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 375 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 376 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 377 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 379 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 380 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 383 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 384 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 385 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 2 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016?2025)
TABLE 3 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 4 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 5 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022?2024
TABLE 6 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
TABLE 7 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
TABLE 8 AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 10 IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 11 IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)
TABLE 12 EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 13 EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)S
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 21 KEY COMPANIES IMPLEMENTING AI
TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 23 KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS.
TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 27 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2023–2030 (NUMBER OF VIALS)
TABLE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 35 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 36 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 37 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 44 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
TABLE 52 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 67 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 75 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)TABLE 80 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 82 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 103 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 104 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 111 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 133 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 155 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 160 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 191 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 196 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 229 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 236 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 237 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 238 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 239 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 240 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 241 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 242 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 244 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 246 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 247 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 248 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 249 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 252 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 253 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 254 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 257 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 261 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 263 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 264 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 266 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 269 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 270 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 271 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 273 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 274 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 277 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 278 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 279 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 282 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 285 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 287 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 289 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 290 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 293 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 295 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 296 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 297 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 298 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 301 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 303 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 306 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 309 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 311 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 312 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 313 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 314 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 318 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 320 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 322 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 323 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 326 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 328 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 330 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 331 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 332 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 334 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 336 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 338 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 339 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 342 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 344 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 346 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 347 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 348 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 350 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 351 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 352 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 354 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 355 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 356 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 358 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 360 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 362 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 363 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 364 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 366 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 368 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 370 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 371 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 372 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 375 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 376 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 377 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 379 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 380 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 383 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 384 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 385 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
In the coming five years, growth in the oligonucleotide synthesis market is likely to be centered on China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos along with an increase in the R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players in the APAC market is another factor driving the growth of this market. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotides manufacturing facility in Singapore to cater to the research companies in the APAC region, thereby establishing its footprint in the APAC market. Such developments are likely to spur the growth of the APAC oligonucleotide synthesis market in the coming years.
The key strategies followed by most companies in the oligonucleotide synthesis market are new product launches; agreements, collaborations, and partnerships; mergers and acquisitions; and expansions. Of all the growth strategies adopted by players in this field, agreements, collaborations, and partnerships accounted for the largest share of XX% of the overall growth strategies from 2010 to 2014. Some leading players adopting these strategies are BioAutomation Corporation (U.S.), Eurofins Genomics (Germany), and GE Healthcare (U.K.). Expansions accounted for the second-largest share of XX% of the overall growth strategies adopted by the players in the market.
The prominent players in the oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), BioAutomation Corporation (U.S.), BioSearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec (Belgium), GE Healthcare (U.K.), Glen Research (U.S.), Gene Link, Inc. (U.S.), GenScript USA Inc. (U.S.), GeneDesign, Inc. (Japan), Integrated DNA Technologies, Inc. (IDT) (U.S.), Link Technologies, Ltd. (U.K.), Nitto Denko Avecia, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).
North America commands the largest share of the global oligonucleotide synthesis market, followed by Europe. However, the European oligonucleotide synthesis market is expected to grow at a slower pace as compared to North America due to the Eurozone debt crisis. The Asia-Pacific market, on the other hand, is in the growth phase and is the fastest-growing region in the global oligonucleotide synthesis market. The growth in the APAC oligonucleotide synthesis market is likely to be centered at China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos and the increase in R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players on the APAC region is another factor driving the growth of this market.
Oligonucleotide synthesis is a highly commoditized market. With its rising attractiveness, an increasing number of companies are moving into this niche market, resulting in price pressure. Oligos have been branded as relatively more expensive research tools as compared to other life sciences research tools. This is further restricting the industry growth, as there are certain limitations related to increasing the cost of oligos. This factor is making it difficult for market players to survive and/or grow at a faster and desired pace. However, market consolidation in the coming years can bring price enhancement in this industry.
The importance of synthetic oligonucleotides as therapeutic drugs for treating diseases has grown significantly over the last decade. Some of the major driving factors for this growth are characterization of more targets following the identification of the human genome, advancements in antisense oligonucleotides, and the development of double stranded small interfering RNA (siRNA). Therapeutic oligos can either be single stranded such as antisense oligonucleotides or double stranded such as siRNA. Furthermore, therapeutic oligos can be useful in treating diseases ranging from viral infections, respiratory diseases, and cancer to rare diseases such as Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis, and Thrombic Thrombocytopenic Purpura.
Currently, only two oligonucleotide-based drugs, namely, Vitravene and Macugen have received market approval and a large number of oligonucleotide-based drugs are in various stages of clinical development in the U.S., Canada, Europe, and other parts of the world. As of 2011, there were over XX oligonucleotide-based drugs in clinical development in the U.S., Europe, and Canada; some of these include antisense oligonucleotides, immunostimulatory oligonucleotides, DNA duplex decoys, siRNAs, ribozymes, microRNAs, aptamers, and spiegelmers. Although most oligonucleotides in clinical development are chemically similar, the mechanisms of their action vary widely. As a result, the development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task.
There are no formal regulatory guidelines available from any regulatory agency for the development of this class of therapeutics. It has been a general practice for regulatory agencies to apply guidelines proposed for small molecules to oligonucleotide therapeutics, owing to their similar characteristics. These include all quality-related regulatory guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Thus, there is a need to address the basic regulatory issues regarding the chemistry, manufacturing, and control of drugs and products belonging to this unique class of therapeutics.
